[1]薛守宇,廉 婷,耿爱民,等.黄芪熟黄散瘀方联合维格列汀与缬沙坦治疗早期糖尿病肾病疗效及对患者血糖和肾功能水平的影响[J].陕西中医,2022,(2):207-210.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.016]
　XUE Shouyu,LIAN Ting,GENG Aimin,et al.Effect of Huangqi Shuhuang Sanyu decoction combined with vildagliptin and valsartan on the levels of CRP,UAER and HbA1c in patients with early diabetic nephropathy[J].,2022,(2):207-210.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.016]
点击复制

黄芪熟黄散瘀方联合维格列汀与缬沙坦治疗早期糖尿病肾病疗效及对患者血糖和肾功能水平的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年2期
页码:
207-210
栏目:
临床研究
出版日期:
2022-02-05

文章信息/Info

Title:
Effect of Huangqi Shuhuang Sanyu decoction combined with vildagliptin and valsartan on the levels of CRP,UAER and HbA1c in patients with early diabetic nephropathy
作者:
薛守宇1;  廉 婷1; 耿爱民2; RASSUL3(哈萨克斯坦)
(1.西安医学院,陕西 西安 710021; 2.长安医院,陕西 西安 710199; 3.陕西中医药大学,陕西 咸阳 712046)
Author(s):
XUE Shouyu; LIAN Ting; GENG Aimin; RASSUL
(Xi'an Medical University,Xi'an 710021,China)
关键词:
早期糖尿病肾病;  黄芪熟黄散瘀方;  肾功能;  维格列汀;  缬沙坦
Keywords:
Early diabetic nephropathy;  Huangqi Shuhuang Sanyu decoction;  Kidney function;  Vildagliptin;  Valsarta
分类号:
R 587.2
DOI:
DOI:10.3969/j.issn.1000-7369.2022.02.016
文献标志码:
A
摘要:
目的:观察黄芪熟黄散瘀方联合维格列汀与缬沙坦治疗早期糖尿病肾病及对患者C反应蛋白(CRP)、24 h尿微量白蛋白排泄率(24 h UAER)、糖化血红蛋白(HbA1c)水平的影响。方法:选取早期糖尿病肾病患者128例,采用随机数字表法分为两组。对照组给予维格列汀联合缬沙坦治疗,观察组在对照组基础上给予黄芪熟黄散瘀方联合治疗。统计两组总有效率,记录两组中医证候积分的水平,检测两组血糖相关指标、肾功能指标及热休克蛋白72(HSP72)、CRP、几丁质酶1(CHIT1)的差异。结果:观察组连续治疗8周后总有效率为90.63%,高于对照组的76.56%,差异有统计学意义(P<0.05)。与治疗前比较,两组的空腹血糖(FBG)、HbA1c、24 h平均血糖(24 h MBG)、平均血糖波动幅度(MAGE)下降,且观察组治疗后血糖相关指标较对照组低(均P<0.05)。与治疗前比较,两组的HSP72、CRP、CHIT1下降,且观察组治疗后HSP72、CRP、CHIT1较对照组低(均P<0.05)。与治疗前比较,两组的血肌酐(SCr)、尿素氮(BUN)、UAER下降,且观察组治疗后肾功能指标较对照组低(均P<0.05)。与治疗前比较,两组的中医证候积分下降,且观察组的中医证候积分较对照组低(P<0.05)。结论:黄芪熟黄散瘀方联合维格列汀与缬沙坦治疗早期糖尿病肾病可降低HSP72、CRP、CHIT1的表达,减轻症状,控制血糖,保护肾脏功能。
Abstract:
Objective:To observe the effects of Huangqi Shuhuang Sanyu decoction combined with vagriptin and valsartan on the levels of C-reactive protein(CRP),24 h urinary microalbumin excretion rate(24 h UAER)and glycosylated hemoglobin(HbAlc)level in patients with early diabetic nephropathy.Methods:A total of 128 cases of early diabetic nephropathy were selected and divided into two groups by random number method.The control group was treated with vilagliptin combined with valsartan,and the observation group was treated with Huangqi Shuhuang Sanyu decoction on the basis of the control group.The total effective rate of the two groups was counted,the level of TCM syndrome score of the two groups was recorded,and the differences of blood glucose related indexes,renal function indexes,HSP72,CRP and CHIT1 between the two groups were detected.Results:After 8 weeks of continuous treatment,the total effective rate of the observation group was 90.63%,which was significantly higher than 76.56% of the control group(P<0.05).Compared with before treatment,the fasting blood glucose(FBG),HbA1c,24 h mean blood glucose(24 h MBG)and mean blood glucose fluctuation(MAGE)in the two groups decreased,and the blood glucose related indexes in the observation group were lower than those in the control group(all P<0.05).Compared with before treatment,HSP72,CRP and CHIT1 in the two groups decreased,and HSP72,CRP and CHIT1 in the observation group were lower than those in the control group after treatment(all P<0.05).Compared with before treatment,SCr,BUN and UAER in the two groups decreased,and the indexes of renal function in the observation group were lower than those in the control group after treatment(all P<0.05).Compared with before treatment,the TCM syndrome score of the two groups decreased,and the TCM syndrome score of the observation group was lower than that of the control group(P<0.05).Conclusion:Huangqi Shuhuang Sanyu decoction combined with vildagliptin and valsartan in the treatment of early diabetic nephropathy can reduce the expression of HSP72,CRP and CHIT1,relieve symptoms,control blood sugar,and protect kidney function.

参考文献/References:

[1] 刘东伟,李征永,刘章锁.糖尿病肾病治疗:立足基点热点、突破靶点焦点[J].中华医学杂志,2021,101(10):683-686.
[2] Archana M,Navale F,Archana P.Antidiabetic and renoprotective effect of anogeissus acuminata leaf extract on experimentally induced diabetic nephropathy[J].Journal of Basic and Clinical Physiology and Pharmacology,2018,29(4):359-364.
[3] 代广玉,修丽梅.糖尿病肾病中医辨证分型研究进展[J].陕西中医,2021,42(1):131-133.
[4] 中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].中华内分泌代谢杂志,2015,31(5):379-385.
[5] 中华医药学会.糖尿病中医防治指南[M].北京:中国中医药出版社,2005:56.
[6] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:72.
[7] Sima A,Nosratollah Z,Younes PS,et al.Serum levels of vaspin and its correlation with nitric oxide in type 2 diabetic patients with nephropathy[J].Current Diabetes Reviews,2018,14(2):162-167.
[8] 赵 亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,42(6):773-775,788.
[9] 于 淼,王秀阁,李瑞恩,等.浅谈糖尿病肾病中医病机[J].新中医,2020,52(18):186-189.
[10] 窦晨辉,陈晓虎,彭书玲.益气养阴通络方对早期糖尿病肾病微炎症状态的影响[J].南京中医药大学学报,2019,35(2):144-147.
[11] 许路军,张国胜,钱宏利.益肾养血方联合西药治疗糖尿病肾病(DKD-Ⅴ期)肾性贫血(脾肾气虚)随机平行对照研究[J].实用中医内科杂志,2019,33(2):35-38.
[12] 胡妮娜,张晓娟.黄芪的化学成分及药理作用研究进展[J].中医药信息,2021,38(1):76-82.
[13] 陈思琦,李佳欣,吴鑫宇,等.熟地黄的药理学研究进展[J].化学工程师,2019,33(11):46-50.
[14] 赵全如,谢晓燕.丹参的化学成分及药理作用研究进展[J].广东化工,2021,48(1):57-59.
[15] 岳 珑,盛 松,王景尚,等.基于网络药理学预测川芎嗪、芍药苷干预糖尿病血管并发症的作用机制[J].中西医结合心脑血管病杂志,2021,19(1):35-40.
[16] 梁晓莲,刘纤纤,李文莉,等.三七总皂苷药理作用及临床应用研究进展[J].湖北农业科学,2021,60(6):15-19.
[17] 郭金铭,周 峰,谭 洋,等.基于网络药理学探讨茯苓治疗糖尿病肾病的研究[J].中成药,2020,42(6):1640-1646.
[18] 刘瑞娟,张 叶,田 伟,等.猪苓的利水渗湿作用及其药理活性研究[J].中国食用菌,2019,38(1):68-71.
[19] 李春梦,王海峰,卢 佩,等.糖尿病肾病患者D-二聚体、纤维蛋白原、胱抑素C检测及临床意义[J].陕西医学杂志,2020,49(11):1503-1506.
[20] Oeckl P,Ludolph AC,Diehl SJ,et al.Chitotriosidase(CHIT1)is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression[J].Journal of Neurology,Neurosurgery and Psychiatry,2018,89(3):239-247.
[21] 王 娟,李爱珍,侯俊秀,等.热休克蛋白72、可溶性髓样细胞触发受体1与2型糖尿病肾损伤的相关性分析[J].现代医学,2020,48(5):618-621.
[22] 陈忠英,巨超龙.血清胱抑素C、β2微球蛋白及尿微量清蛋白与尿肌酐比值在早期2型糖尿病肾病患者诊断中的临床意义[J].陕西医学杂志,2017,46(4):467-468.

备注/Memo

备注/Memo:
基金项目:陕西省教育厅课题(21JP114)
更新日期/Last Update: 2022-02-09